Movetis Articles
Shire says 2nd-qtr 2010 revenues rose 35% and EPS leapt 71%; updates on Firazyr; Movetis’ Resolor cleared in Switzerland
5 August 2010
Showing 1-2 of 2 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
